US FDA Committee to review AstraZeneca's Imfinzi to treat resectable NSCLC based on AEGEAN phase III trial results
The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s Imfinzi (durvalumab) met the primary endpoint of event-free survival (EFS) in the treatment of resectable non-small cell lung cancer (NSCLC) …